In a major boost to the nation’s healthcare infrastructure, Sam Pharmaceuticals Ltd has officially commissioned its ultra-modern manufacturing facility in Lagos.
The expansion is being celebrated as a pivotal milestone in Nigeria’s journey toward pharmaceutical self-sufficiency and reduced over-reliance on imported medicines.
Regulatory Reforms Drive Industrial Growth
The ceremony served as a platform for industry stakeholders to laud the Director-General of NAFDAC, Prof. Mojisola Adeyeye, for her transformative leadership. Attendees credited her tenure with creating a transparent regulatory environment that prioritizes quality, safety, and local capacity development.
Experts at the event specifically highlighted NAFDAC’s 5+5 Policy as the primary catalyst for this industrial surge. The policy, which encourages importers to migrate toward local production, has been instrumental in increasing domestic output and bolstering investor confidence across the pharmaceutical value chain.
Commitment to National Drug Security
Speaking on the importance of the new facility, NAFDAC representatives reaffirmed the Agency’s dedication to upholding global best practices while supporting indigenous manufacturers. The Agency emphasized that a robust local manufacturing sector is the only sustainable path to ensuring safe, effective, and affordable medicines for all Nigerians.
“NAFDAC reaffirmed its commitment to fostering a robust and self-sufficient pharmaceutical sector, ensuring the availability of safe, effective, and affordable medicines for Nigerians,” as stated on X.
A Vision for Future Collaboration
The commissioning marks a broader shift in the Nigerian health sector, where regulatory reforms are directly translating into physical infrastructure and job creation. Moving forward, NAFDAC maintains that sustained collaboration between regulators and private industry players remains the critical engine for achieving national drug security and superior healthcare outcomes for the populace.
Share this
